ANGO vs NPCE: fair value comparison
AngioDynamics, Inc. and NeuroPace, Inc. · Updated 2026-10-19
ANGO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NPCE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NPCE currently ranks higher by quality score.
| ANGO | NPCE | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.24 | $12.24 |
| 12-month range | $9.70–$16.13 | $9.40–$19.29 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #167 of 301 Healthcare | #166 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | — | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: ANGO fair value analysis · NPCE fair value analysis